Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause
08:36am, Thursday, 26'th Mar 2026
Novo Nordisk (NYSE:NVO) has received a broadly neutral assessment from Deutsche Bank and Citi after a series of clinical and commercial updates, with both brokers flagging encouraging but not transfor
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
06:46pm, Wednesday, 25'th Mar 2026
Novo Nordisk (NVO) closed the most recent trading day at $36.33, moving 1.52% from the previous trading session.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
01:26pm, Wednesday, 25'th Mar 2026
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
Novo Nordisk cuts Wegovy price in South Africa for a second time
01:12pm, Wednesday, 25'th Mar 2026
Novo Nordisk is cutting South African prices of its weight-loss drug Wegovy for a second time since it launched in August, local executives said on Wednesday, pointing to fierce competition in a ma
Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results
02:54am, Wednesday, 25'th Mar 2026
The drugmaker said UBT251 achieved mean body weight reduction of up to 9.8% after a 24-week trial.
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter
12:17pm, Tuesday, 24'th Mar 2026
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO),
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter
12:01pm, Tuesday, 24'th Mar 2026
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed...
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer
08:56am, Tuesday, 24'th Mar 2026
The company recently obtained approval for a higher-dose version of Wegovy.
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
12:30pm, Monday, 23'rd Mar 2026
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
11:56am, Monday, 23'rd Mar 2026
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of stability vs. upside.
Novo Nordisk: Priced For Disaster
11:35am, Monday, 23'rd Mar 2026
Novo Nordisk shares have slumped despite a promising partnership with Hims & Hers Health to distribute semaglutide drugs via telehealth platform. The agreement grants HIMS access to FDA-approved Ozemp
Novo Nordisk Begins Study of Lexicon Oral Obesity Drug
08:47am, Monday, 23'rd Mar 2026
The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and biological impacts.
Novo Nordisk A/S - share repurchase programme
08:19am, Monday, 23'rd Mar 2026
Bagsværd, Denmark, 23 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
06:10am, Monday, 23'rd Mar 2026
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices.
Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy
03:22am, Monday, 23'rd Mar 2026
At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched pric
